LDS/Medical Tests/ADAMTS13 Activity and Inhibitor Assay

ADAMTS13 Activity and Inhibitor Assay

ADAMTS13 is a disintegrin and metalloprotease with a thrombospondin type 1 motifs, member 13 that cleaves the platelet-adhesive plasma protein von Willebrand factor (VWF) at the peptide bond Try1605-Met1606 to disrupt VWF-induced platelet aggregation. Congenital thrombotic thrombocytopenic purpura (TTP), also known as Upshaw-Schulman syndrome, is a rare autosomal recessive disease due to the mutation of the ADAMTS13 gene. This results in a defective production of ADAMTS13. Estimated incidence is 4-6 cases per million. Many cases of idiopathic TTP are associated with acquired anti-ADAMTS13 autoantibody that neutralizes the activity of ADAMTS13 and enhances its removal from the circulation. Therefore, TTP often characterized by the decreased activity of ADAMTS13.

The deficiency of ADAMTS13 results in failure to cleave VWF:multimers, leading to the formation of ultra-large-molecular weight VWF. This causes an unrestricted growth of microvascular thrombi and ultimately clinical manifestations of TTP. TTP is classically characterized by the pentad of thrombocytopenia, anemia, fever, neurologic, and renal abnormalities. Presence of thrombocytopenia and microangiopathic hemolytic anemia (MAHA) without other clinically apparent causes are diagnostic for TTP. Prompt diagnosis and treatment with plasma exchange can be life-saving. Therefore, the measurement of ADAMTS13 activity can be valuable in the diagnosis. ADAMTS13 activity assay should be first used to evaluate the percent activity. If the ADAMTS13 activity assay is <30%, an inhibitor screen should be performed to look for specific ADAMTS13 inhibition. If specific inhibition is apparent, the titer of the inhibitor should be performed and reported.

  • Aids in diagnosis of congenital or acquired thrombotic thrombocytopenic purpura
  • Therapy monitoring and disease management

Activity of <10% ADAMTS13 is highly indicative of thrombotic thrombocytopenic purpura
The presence of ADAMTS13 inhibition (positive inhibitor screen) with a measurable antibody titer is most consistent with an acquired TTP

Decreased in:

  • Congenital and acquired Thrombotic thrombocytopenic purpura (TTP)
  • Hemolytic uremic syndrome
  • Hematopoietic stem cell transplantation
  • Solid organ transplantation
  • Liver disease
  • Disseminated intravascular coagulation
  • Sepsis
  • Metastatic malignancy
  • Pregnancy
  • Drug-induced (clopidogrel, cyclosporine, mitomycin C, ticlopidine, tacrolimus)

> 70 % activity ADAMTS13 Inhibitor Screen: Negative

Fluorescence Resonance Energy Transfer (FRET), Enzyme immunoassay (EIA).

Platelet-poor plasma (Light-blue top/citrate). Plasma must be stored below -40 C soon after separation.

Transportation: frozen (dry ice)

Stability

  • Ambient - 2 hours
  • Frozen - 2 weeks
ADAMTS13 inhibitor screen, von Willebrand factor antigen assay (VWF:Ag), von Willebrand factor immunoactivity, VWF:multimer assay, platelet count, coagulation profile.
1-3 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login